Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Crelosidenib

Copy Product Info
😃Good
Catalog No. T39716Cas No. 2230263-60-0
Alias Mutant IDH1-IN-6, LY3410738, LY 3410738

Crelosidenib is a potent and selective mutant IDH inhibitor with IC50s of 6.27 nM, 3.71 nM, 36.9 nM, and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q, and IDH2 R172K mutases, respectively, and low inhibitory activity against the wild-type IDH enzyme.

Crelosidenib

Crelosidenib

Copy Product Info
😃Good
Purity: 98.54%
Catalog No. T39716Alias Mutant IDH1-IN-6, LY3410738, LY 3410738Cas No. 2230263-60-0
Crelosidenib is a potent and selective mutant IDH inhibitor with IC50s of 6.27 nM, 3.71 nM, 36.9 nM, and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q, and IDH2 R172K mutases, respectively, and low inhibitory activity against the wild-type IDH enzyme.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$397-In Stock
5 mg$970-In Stock
10 mg$1,290-In Stock
25 mg$1,950-In Stock
50 mg$2,620-In Stock
100 mg$3,530-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.54%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Crelosidenib is a potent and selective mutant IDH inhibitor with IC50s of 6.27 nM, 3.71 nM, 36.9 nM, and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q, and IDH2 R172K mutases, respectively, and low inhibitory activity against the wild-type IDH enzyme.
Targets&IC50
HT1080 cells:1.28 nM
In vitro
Crelosidenib (Example 2) suppresses 2-hydroxyglutarate production in HT1080 cells with an IC₅₀ of 1.28 nM, demonstrating effective inhibition of mutant IDH1 R132C activity in a cellular context. The level of α-ketoglutarate (aKG), a product of wild-type IDH1, remains unchanged, confirming the compound’s selectivity for the mutant enzyme over the wild-type form[1].
In vivo
Treatment with Crelosidenib (Example 2) via oral gavage at doses ranging from 0 to 32 mg/kg, administered twice daily for 3 days, resulted in a dose-dependent reduction of 2-hydroxyglutarate levels in xenograft mice bearing IDH1 mutations[1].
SynonymsMutant IDH1-IN-6, LY3410738, LY 3410738
Chemical Properties
Molecular Weight504.62
FormulaC28H36N6O3
Cas No.2230263-60-0
Smiles[C@H](CC1CC1)(C2=CC=C([C@@H](NC=3N=C4C(=CN3)COC(=O)N4CC)C)C=C2)N5CCN(C(C=C)=O)CC5
Relative Density.1.251 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Crelosidenib | purchase Crelosidenib | Crelosidenib cost | order Crelosidenib | Crelosidenib chemical structure | Crelosidenib in vivo | Crelosidenib in vitro | Crelosidenib formula | Crelosidenib molecular weight